Dean J. Mitchell
Dean J. Mitchell's purchase track record
How the stock did after each of Dean J. Mitchell's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/22/2023 | PGEN | $35K | -10.0% | 0.0% | +21.2% |
| 3/24/2023 | PRAX | $42K | +39.5% | +76.3% | +8.8% |
| 6/8/2022 | PRAX | $45K | +76.1% | +14.4% | -4.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precigen mentioned in Zacks analyst blog. Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.
Transaction History
| PRAX | ▲ Buy | Grant | 1,371 | $0 | 6/10/2026 | View on chart |
| PRAX | ▲ Buy | Option Exercise | 8,566 | $379K | 9/24/2025 | View on chart |
| PRAX | ▲ Buy | Option Exercise | 1,753 | $77K | 9/24/2025 | View on chart |
| PRAX | ▲ Buy | Option Exercise | 1,932 | $28K | 9/24/2025 | View on chart |
| PGEN | ▲ Buy | Grant | 39,510 | $56K | 3/14/2024 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 106,837 | — | 3/9/2024 | View on chart |
| PGEN | ▲ Buy | Open Market | 25,000 | $35K | 9/22/2023 | View on chart |
| PRAX | ▲ Buy | Open Market | 50,000 | $42K | 3/24/2023 | View on chart |
| PGEN | ▲ Buy | Grant | 48,290 | $56K | 3/9/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 61,576 | — | 2/22/2023 | View on chart |
| PRAX | ▲ Buy | Open Market | 25,000 | $45K | 6/8/2022 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 16,212 | — | 3/25/2022 | View on chart |
| PGEN | ▲ Buy | Grant | 27,832 | $56K | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Praxis Precision Announces Inducement Grants Under Nasdaq Rule
Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.
Praxis Precision Announces Inducement Grants Under Nasdaq Rule. Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.